NBIX vs. PFE: Neurocrine Biosciences vs. Pfizer Stock Comparison
How do Neurocrine Biosciences (NBIX) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Neurocrine Biosciences (NBIX) and Pfizer (PFE) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while PFE is classified in Pharmaceuticals.
| Profile Item | NBIX | PFE |
|---|---|---|
| Name | Neurocrine Biosciences, Inc. | Pfizer Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 16.66 billion USD | 167.52 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 23, 1996 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Total Return (1Y) | 9.40% | 28.65% |
| Total Return (3Y, Annualized) | 14.12% | 6.41% |
| Total Return (5Y, Annualized) | 12.61% | -3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Volatility (1Y, Annualized) | 35.05% | 21.72% |
| Beta (5Y) | 0.29 | 0.35 |
| Max Drawdown (5Y) | -42.89% | -58.96% |
| Avg. Volume (3M) | 1.31M | 33.67M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Sharpe Ratio (1Y) | 0.15 | 1.12 |
| Sortino Ratio (1Y) | 0.22 | 1.73 |
Profitability
ROE (TTM)
Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Pfizer (PFE) at 4.47% is closer to the peer norm — stronger capital efficiency for NBIX.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.42%
- Max
- 109.18%
- NBIX
- 20.42%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Neurocrine Biosciences (NBIX) at 18.98% keeps the most of each sales dollar — above its industry’s net margin range — and Pfizer (PFE) at 6.34% also retains a top-quartile share.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.98%
- NBIX
- 18.98%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Neurocrine Biosciences (NBIX) at 31.98% and Pfizer (PFE) at 33.38% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.98%
- Max
- 83.12%
- NBIX
- 31.98%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | NBIX | PFE |
|---|---|---|
| ROE (TTM) | 20.42% | 4.47% |
| ROA (TTM) | 12.45% | 5.59% |
| Net Margin (TTM) | 18.98% | 6.34% |
| Operating Margin (TTM) | 31.98% | 33.38% |
| Gross Margin (TTM) | 64.67% | 74.90% |
Growth
Revenue Growth
Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Both Neurocrine Biosciences (NBIX) at 41.95% and Pfizer (PFE) at -3.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Revenue Growth (YoY) | 21.45% | -1.65% |
| Revenue Growth (3Y CAGR) | 24.32% | -14.80% |
| EPS Growth (YoY) | 41.95% | -3.55% |
| EPS Growth (3Y CAGR) | 44.12% | -37.12% |
Financial Strength
Current Ratio (MRQ)
Both Neurocrine Biosciences (NBIX) at 2.04 and Pfizer (PFE) at 1.42 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.04
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- NBIX
- 2.04
- Min
- 0.10
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
Debt / Equity (MRQ)
Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.12
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- NBIX
- 0.12
- Q1
- 0.02
- Min
- 0.00
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Current Ratio (MRQ) | 2.04 | 1.42 |
| Debt / Equity (MRQ) | 0.12 | 0.71 |
| Net Debt / EBITDA | -0.27 | 1.97 |
Dividends
Dividend Yield (TTM)
Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%).
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- NBIX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | NBIX | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 7.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 245.71% |
Valuation
P/E Ratio (TTM)
Both Neurocrine Biosciences (NBIX) at 24.43 and Pfizer (PFE) at 41.99 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
24.43
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- NBIX
- 24.43
- Q1
- 13.30
- Min
- 0.07
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Pfizer (PFE) at 2.63 sits in the cheaper P/S ratio quartile while Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s middle — PFE costs less per dollar of sales, though read it alongside growth and margins.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- NBIX
- 4.50
- Q1
- 3.01
- Min
- 0.01
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Neurocrine Biosciences (NBIX) at 4.30 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.
NBIX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.30
- Max
- 13.53
- Q3
- 6.54
- NBIX
- 4.30
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | NBIX | PFE |
|---|---|---|
| P/E Ratio (TTM) | 24.43 | 41.99 |
| P/S Ratio (TTM) | 4.50 | 2.63 |
| P/B Ratio (MRQ) | 4.30 | 1.88 |
| Free Cash Flow Yield (TTM) | 6.11% | 7.76% |